Skip to main content
TipRanks
Go Ultimate75% OFF

Advanced Enzyme Technologies Ltd (ADVENZYMES) AI Stock Analysis

1 Followers
IN:ADVENZYMES

Advanced Enzyme Technologies Ltd

(NSE:ADVENZYMES)

Select Model
Rating:70Outperform
Price Target:INR 310.00â–²(10.28% Upside)
Action:reiterated
Date:11/03/26

The score is driven primarily by strong financial quality—minimal leverage, healthy profitability, and solid cash generation. This is tempered by weaker longer-term technical signals (below key medium/long moving averages with negative MACD) and only moderate valuation support with a low dividend yield.

Positive Factors
Very low leverageMinimal leverage gives the company substantial financial flexibility and keeps solvency risk low. A strong equity base allows Advanced Enzyme Technologies to fund operations, absorb business volatility, and pursue growth without relying heavily on debt or exposing cash flow to large financing costs.
Negative Factors
Margin normalizationMargin compression from prior peaks indicates that historical profitability levels may not be fully repeatable. If normalization persists, revenue growth will translate less efficiently into earnings, limiting operating leverage and potentially reducing the funds available for reinvestment despite healthy current margins.

Advanced Enzyme Technologies Ltd (ADVENZYMES) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%IN:ADVENZYMES-9.57%INDA-5.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 31.72B
Dividend Yield
0.48%
Average Volume (3M)
9,761
Price to Earnings (P/E)
18.4
Beta (1Y)
0.94
Revenue Growth
10.31%
EPS Growth
15.98%
Country
India
Employees
409
Sector
Healthcare
Sector Strength
51
Industry
Chemicals - Specialty

Advanced Enzyme Technologies Ltd Business Overview & Revenue Model

Company Description

Advanced Enzyme Technologies Limited, headquartered in Thane, India, is a global company engaged in the research, development, manufacturing, and marketing of enzymes and probiotics. Its operations span India, the United States, Asia, and Europe. The...

Advanced Enzyme Technologies Ltd Financial Statement Overview

Summary

Strong overall fundamentals supported by an exceptionally conservative balance sheet (very low leverage), healthy profitability (net margins generally ~20%+), and reliable operating cash generation. Offsetting factors include margin compression versus peak FY2021–FY2022 levels and uneven year-to-year free cash flow growth.

Income Statement

78Positive

Balance Sheet

92Very Positive

Cash Flow

83Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue7.80B7.46B6.37B6.23B5.41B5.29B
Gross Profit3.66B3.50B3.07B4.64B3.98B4.09B
EBITDA2.63B2.75B2.27B2.27B1.79B2.09B
Net Income1.71B1.69B1.31B1.33B1.06B1.20B
Balance Sheet
Total Assets19.06B18.39B16.21B15.35B14.22B12.68B
Cash, Cash Equivalents and Short-Term Investments6.73B7.00B5.88B5.48B4.86B3.74B
Total Debt536.99M320.09M393.50M473.08M334.99M347.30M
Total Liabilities1.86B1.56B1.53B1.64B1.38B1.27B
Stockholders Equity16.65B16.32B14.21B13.24B12.35B10.89B
Cash Flow
Free Cash Flow01.20B1.15B990.56M1.02B941.15M
Operating Cash Flow01.73B1.49B1.41B1.40B1.22B
Investing Cash Flow0-923.39M-990.44M-646.49M-2.98B-249.12M
Financing Cash Flow0-679.45M-692.02M-592.38M-257.98M-273.75M

Advanced Enzyme Technologies Ltd Technical Analysis

Technical Analysis SentimentNeutral
Last Price281.10

Price Trends

50DMA278.34Positive
100DMA295.32Negative
200DMA308.21Negative

Market Momentum

MACD2.62Negative
RSI55.03Neutral
STOCH51.58Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ADVENZYMES, the sentiment is Neutral. The current price of 281.10 is above the 20-day moving average (MA) of 272.11, above the 50-day MA of 278.34, and below the 200-day MA of 308.21, indicating a neutral trend. The MACD of 2.62 indicates Negative momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 51.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ADVENZYMES.

Advanced Enzyme Technologies Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:ADVENZYMES against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ADVENZYMESIN:ADVENZYMES70OutperformINR 31.48B18.39―0.48%10.31%15.98%
IN:ROSSARIIN:ROSSARI65NeutralINR 23.89B15.69―0.12%19.76%11.74%
IN:AVTNPLIN:AVTNPL63NeutralINR 15.72B15.53―0.77%41.25%65.19%
IN:JUBLINGREAIN:JUBLINGREA61NeutralINR 93.24B26.42―0.85%15.41%21.76%
IN:NEOGENIN:NEOGEN55NeutralINR 84.02B186.22―0.04%26.66%51.16%
IN:VIDHIINGIN:VIDHIING55NeutralINR 15.36B25.22―1.95%34.77%25.92%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%IN:ADVENZYMESIN:AVTNPLIN:JUBLINGREAIN:NEOGENIN:ROSSARIIN:VIDHIINGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ADVENZYMES and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ADVENZYMESAdvanced Enzyme Technologies Ltd281.10-34.54-10.94%
IN:AVTNPLAVT Natural Products Limited103.2035.4152.23%
IN:JUBLINGREAJubilant Ingrevia Ltd.585.40-129.38-18.10%
IN:NEOGENNeogen Chemicals Ltd.2796.551552.55124.80%
IN:ROSSARIRossari Biotech Ltd431.30-183.70-29.87%
IN:VIDHIINGVidhi Specialty Food Ingredients Ltd305.30-62.80-17.06%

Advanced Enzyme Technologies Ltd Corporate Events

Advanced Enzyme promoter group member seeks shift to public shareholder status

Oct 20, 2026

Advanced Enzyme Technologies has disclosed that a promoter group member, Snehal Shamsunder Soni, holding 15,000 equity shares amounting to 0.01% of the company’s share capital, has formally requested reclassification from the promoter group category...

Advanced Enzymes Promoter Group Member Seeks Reclassification as Public Shareholder

Oct 19, 2026

Advanced Enzyme Technologies has informed the stock exchanges that it received a request from promoter group member Pratik Prakash Kokane to reclassify his 10,000 shares, representing 0.01% of equity, from promoter group to public shareholder under S...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026